Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (61-70 of 266) with videos related to

Pageof 27
Sort By:
Oncoimmunology|April 28, 2022
Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasisAlberto Carretero-González, Marta Hergueta-Redondo, Sara Sánchez-Redondo, et al.
The Oncologist|September 23, 2022
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted TherapyToni K Choueiri, Camillo Porta, Cristina Suárez, et al.
Cancer Metastasis Reviews|July 20, 2010
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populationsEmiliano Calvo, Pablo Maroto, Xavier García del Muro, et al.
Cancer Metastasis Reviews|July 20, 2010
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinomaEmiliano Calvo, Pablo Maroto, Xavier García del Muro, et al.
Atherosclerosis|May 19, 2019
Role of epicardial adipose tissue NPR-C in acute coronary syndromeInmaculada Moreno-Santos, Manuel Macías-González, Carlos Porras-Martín, et al.
Expert Opinion on Drug Safety|July 9, 2014
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access programDaniel Castellano, Luis M Antón Aparicio, Emilio Esteban, et al.
Oncotarget|December 1, 2016
Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patientsXiaoyan Liu, Jesse J Swen, Epie Boven, et al.
Japanese Journal of Clinical Oncology|March 19, 2021
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive diseaseHiroyoshi Suzuki, Daniel Castellano, Johann de Bono, et al.
Frontiers in Microbiology|October 21, 2017
Role of Gut Microbiota on Cardio-Metabolic Parameters and Immunity in Coronary Artery Disease Patients with and without Type-2 Diabetes MellitusLidia Sanchez-Alcoholado, Daniel Castellano-Castillo, Laura Jordán-Martínez, et al.
Oncotarget|December 14, 2020
A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trialGuillermo de Velasco, Lucia Carril-Ajuria, Felix Guerrero-Ramos, et al.
Pageof 27

Showing results (61-70 of 266) with videos related to

Sort By:
Pageof 27
Oncoimmunology|April 28, 2022
Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasisAlberto Carretero-González, Marta Hergueta-Redondo, Sara Sánchez-Redondo, et al.
The Oncologist|September 23, 2022
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted TherapyToni K Choueiri, Camillo Porta, Cristina Suárez, et al.
Cancer Metastasis Reviews|July 20, 2010
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populationsEmiliano Calvo, Pablo Maroto, Xavier García del Muro, et al.
Cancer Metastasis Reviews|July 20, 2010
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinomaEmiliano Calvo, Pablo Maroto, Xavier García del Muro, et al.
Atherosclerosis|May 19, 2019
Role of epicardial adipose tissue NPR-C in acute coronary syndromeInmaculada Moreno-Santos, Manuel Macías-González, Carlos Porras-Martín, et al.
Expert Opinion on Drug Safety|July 9, 2014
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access programDaniel Castellano, Luis M Antón Aparicio, Emilio Esteban, et al.
Oncotarget|December 1, 2016
Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patientsXiaoyan Liu, Jesse J Swen, Epie Boven, et al.
Japanese Journal of Clinical Oncology|March 19, 2021
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive diseaseHiroyoshi Suzuki, Daniel Castellano, Johann de Bono, et al.
Frontiers in Microbiology|October 21, 2017
Role of Gut Microbiota on Cardio-Metabolic Parameters and Immunity in Coronary Artery Disease Patients with and without Type-2 Diabetes MellitusLidia Sanchez-Alcoholado, Daniel Castellano-Castillo, Laura Jordán-Martínez, et al.
Oncotarget|December 14, 2020
A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trialGuillermo de Velasco, Lucia Carril-Ajuria, Felix Guerrero-Ramos, et al.
Pageof 27